Research programme: monoclonal antibodies and small molecule therapeutics - MediaPharma

Drug Profile

Research programme: monoclonal antibodies and small molecule therapeutics - MediaPharma

Alternative Names: mab EV20; MP BF 001; MP-1959 (SP-2); MP-3546; MP-AA-1; MP-E-8-3/1959; MP-E-8.3; MP-EV-20; MP-EV20-DC54; MP-EV20-RT; MP-HE-001A; MP-HE-001B; MP-HE-001C; MP-PN-1; MP-PN-2; MP-RM-1 (ErbB-3 antibody)

Latest Information Update: 18 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MediaPharma
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Carrier protein inhibitors; CD248 antigen inhibitors; Epidermal growth factor receptor modulators; ERBB-3 receptor antagonists; Hypoxia-inducible factor 1 inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; Receptor protein-tyrosine kinase modulators; Transcriptional elongation factor inhibitors; Transcriptional elongation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Diabetic foot ulcer; Pancreatic cancer; Phaeochromocytoma; Renal cell carcinoma; Stroke; Von Hippel-Lindau disease

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 08 Sep 2016 Preclinical trials in Pancreatic cancer in Italy (unspecified route) before September 2016
  • 08 Sep 2016 Preclinical trials in Phaeochromocytoma in Italy (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top